Last reviewed · How we verify
Abobotulinumtoxin A
Abobotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Abobotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Abobotulinumtoxin A |
|---|---|
| Also known as | Dysport |
| Sponsor | Neurology Center of New England P.C. |
| Drug class | Botulinum toxin |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
This botulinum toxin serotype A derivative irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. By preventing neurotransmitter release, it produces localized muscle relaxation lasting 3-4 months. The effect is temporary as the body regenerates new nerve terminals.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Spasticity
- Chronic migraine
- Hyperhidrosis
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness
- Neck pain
- Antibody formation (neutralizing)
Key clinical trials
- DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia (PHASE1, PHASE2)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (PHASE4)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |